Startups
NKore is combining proprietary-cellular and protein-based diagnostics, novel AI analytics and a natural, proprietary approach to “Super Charging” allogeneic Natural Killer Cells to deploy a new era in immuno-therapeutic medicine for the treatment of cancer in patients of all ages. At NKore, patients come first!
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 29, 2026 | FDA Grants NKore BioTherapeutics, Inc. a Type B Pre-IND Meeting for Lead Supercharged NK Cell Therapy Candidate NK101 | NKore The scheduled meeting marks the Company's first formal regulatory interaction with the FDA in support of a planned U.S. IND filing This meeting represents the beginning of an important regulatory dialogue with the FDA rather than an e... |
| Sep 5, 2022 | NKORE Discovery in Cancer Treatment Featured Live in Moonshot4Kids Congressional and Administration Briefing Recap Event | Dr. Jewett and Tracy Ryan give live presentation on NKORE Biotherapeutics discovery, Saturday, Sept 10 Help us make history for childhood cancer awareness. Tell your Rep to support H. Res. 404 today! Childhood cancer advocate Janet Demeter ... |
Reviews 0
FAQ about NKore
What has the press written about NKore?
Parsers VC has collected 3 articles mentioning NKore, among them “FDA Grants NKore BioTherapeutics, Inc. a Type B Pre-IND Meeting for Lead Supercharged NK Cell Therapy Candidate NK101” (Jul 29, 2026) and “NKORE Discovery in Cancer Treatment Featured Live in Moonshot4Kids Congressional and Administration Briefing Recap Event” (Sep 5, 2022).
Is NKore still active?
Yes, NKore is active; its latest activity on Parsers VC dates from Oct 1, 2026.